UNSPSC 51142569: Rasagiline methanesulfonate

This classification denotes a monoamine oxidase inhibitor and antiparkinsonian agent with the molecular formula C12H13N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LH8C2JI290, chemically known as (r)-n-2-propynyl-1-indanamine methanesulfonate, but more generally known as rasagiline methanesulfonate, which bears US NIH Compound Identifier 3052775. European Medicines Agency schedules rasagiline methanesulfonate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10261MIG.

Most nations, for tariff purposes, schedule rasagiline methanesulfonate under HS 29214980. SMILES: CS(=O)(=O)O.C#CCN[C@@H]1CCC2C1CCCC2.

UNSPSC 51142569 Rasagiline methanesulfonate is a Commodity code covering a specific pharmaceutical product, but the recent state and local activity recorded under this code does not align with its nominal scope. Seminole County, Florida's IFB60459723LAS procurement, posted June 30, 2026 with a response deadline of July 26, 2023, solicits Naloxone and safe drug deactivation systems — opioid reversal agents and drug disposal equipment — rather than rasagiline, a Parkinson's disease medication. The mismatch suggests either a classification error in the opportunity record or a data inconsistency. State and local governments purchasing under pharmaceutical UNSPSC codes typically source medications through established health department or county health system procurement channels, often leveraging cooperative purchasing agreements or framework contracts with pharmaceutical distributors. This particular code shows minimal recent relevant activity that aligns with its stated pharmaceutical scope.

The single identified opportunity originates from a county health department in Florida. Geographic activity in the source is limited to Florida, with no additional states represented in recent solicitations. Without additional recent procurement records tagged to this code that reflect actual rasagiline purchases or related Parkinson's disease pharmaceutical procurement, the code shows insufficient market signal to support a targeted pursuit strategy at this time.